Certara to Report Second Quarter 2022 Financial Results on August 9th, 2022
July 12, 2022 08:00 ET
|
Certara
PRINCETON, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of...
Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development
June 28, 2022 08:00 ET
|
Certara
PRINCETON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Discovery Simulator, a new software designed for...
Certara Announces New Versions of Biosimulation Software for Development of Novel Biologics
June 21, 2022 08:00 ET
|
Certara
PRINCETON, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Certara Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of new versions of its Immunogenicity (IG),...
Certara Reports First Quarter 2022 Financial Results
May 05, 2022 16:15 ET
|
Certara
PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2022. ...
Certara to Participate in Upcoming Investor Conferences
May 03, 2022 16:30 ET
|
Certara
PRINCETON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor...
Certara to Report First Quarter 2022 Financial Results on May 5th, 2022
April 20, 2022 08:00 ET
|
Certara
PRINCETON, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of...
Certara Reports Fourth Quarter and Full Year 2021 Financial Results
March 01, 2022 16:15 ET
|
Certara
PRINCETON, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter and full year of 2021...
U.S. FDA Licenses Certara’s Immunogenicity Simulator
February 23, 2022 16:30 ET
|
Certara
PRINCETON, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has licensed...
在过去8年中，美国FDA每一年批准的新药中90%来自Certara的客户
February 22, 2022 01:26 ET
|
Certara USA, Inc.
新泽西州普林斯顿 , Feb. 22, 2022 (GLOBE NEWSWIRE) -- 全球生物模拟领域的领军企业Certara, Inc.（纳斯达克股票代码：CERT），今日宣布在2021年美国食品药品监督管理局 (FDA) 药品审评和研究中心 (CDER)...
Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 8th Consecutive Year
February 15, 2022 16:30 ET
|
Certara
PRINCETON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that 90 percent of new drug approvals by the U.S. Food and Drug...